|Signatures of mutational processes in human cancer|
LB Alexandrov, S Nik-Zainal, DC Wedge, SAJR Aparicio, S Behjati, ...
Nature 500 (7463), 415-421, 2013
|COSMIC: exploring the world's knowledge of somatic mutations in human cancer|
SA Forbes, D Beare, P Gunasekaran, K Leung, N Bindal, H Boutselakis, ...
Nucleic acids research 43 (D1), D805-D811, 2015
|Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK|
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247, 2009
|Systematic identification of genomic markers of drug sensitivity in cancer cells|
MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ...
Nature 483 (7391), 570-575, 2012
|A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations|
SV Sharma, DY Lee, B Li, MP Quinlan, F Takahashi, S Maheswaran, ...
Cell 141 (1), 69-80, 2010
|Prospective derivation of a living organoid biobank of colorectal cancer patients|
M van de Wetering, HE Francies, JM Francis, G Bounova, F Iorio, A Pronk, ...
Cell 161 (4), 933-945, 2015
|Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells|
W Yang, J Soares, P Greninger, EJ Edelman, H Lightfoot, S Forbes, ...
Nucleic acids research 41 (D1), D955-D961, 2012
|The evolutionary history of lethal metastatic prostate cancer|
G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, JMC Tubio, ...
Nature 520 (7547), 353-357, 2015
|A landscape of pharmacogenomic interactions in cancer|
F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ...
Cell 166 (3), 740-754, 2016
|Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma|
C Montagut, SV Sharma, T Shioda, U McDermott, M Ulman, LE Ulkus, ...
Cancer research 68 (12), 4853-4861, 2008
|Targeting MYCN in neuroblastoma by BET bromodomain inhibition|
A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ...
Cancer discovery 3 (3), 308-323, 2013
|Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors|
U McDermott, AJ Iafrate, NS Gray, T Shioda, M Classon, S Maheswaran, ...
Cancer research 68 (9), 3389-3395, 2008
|Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma|
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5 (1), 1-15, 2014
|Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine|
D Dias‐Santagata, S Akhavanfard, SS David, K Vernovsky, G Kuhlmann, ...
EMBO molecular medicine 2 (5), 146-158, 2010
|MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling|
S Huang, M Hölzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ...
Cell 151 (5), 937-950, 2012
|Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling|
U McDermott, SV Sharma, L Dowell, P Greninger, C Montagut, J Lamb, ...
Proceedings of the National Academy of Sciences 104 (50), 19936-19941, 2007
|Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue|
CS Cooper, R Eeles, DC Wedge, P Van Loo, G Gundem, LB Alexandrov, ...
Nature genetics 47 (4), 367-372, 2015
|Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties|
MP Menden, F Iorio, M Garnett, U McDermott, CH Benes, PJ Ballester, ...
PLoS one 8 (4), e61318, 2013
|Genomics and the continuum of cancer care|
U McDermott, JR Downing, MR Stratton
New England Journal of Medicine 364 (4), 340-350, 2011
|A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia|
K Tzelepis, H Koike-Yusa, E De Braekeleer, Y Li, E Metzakopian, ...
Cell reports 17 (4), 1193-1205, 2016